Investor’s Watch List: Kohl’s Corporation (NYSE:KSS), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

On Wednesday, Shares of Kohl’s Corporation (NYSE:KSS), added 3.93% and closed at $45.70 in the last trading session. The last trading range of the stock ranges between $43.00 and $46.25. Kohl’s Department Stores (KSS) recently declared that its chief financial officer, Wesley S. McDonald, intends to retire in late Spring 2017 after 14 years of service with the company.

“Wes has played an important role in the company’s growth and development over the last 14 years. His business knowledge and financial expertise have been critical in our success and his communication with the investment community has always been transparent and consistent,” said Kevin Mansell, Kohl’s chairman, chief executive officer and president. “On behalf of the entire executive leadership team, I thank Wes for his noteworthycontributions, and I look forward to his continued contribution during this transition. He will be missed on his departure, and we wish him the very best in his retirement.”

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), jumped 11.92% and closed at $92.88 in the last trading session. The last trading range of the stock ranges between $87.79 and $93.80. The company’s Market capitalization is $22.97 Billion with the total Outstanding Shares of 148.03 million. Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their CFTR gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 6 years of age and older who have the G551D mutation in their CFTR gene. The company also develops VX-661, a corrector compound that is in a Phase III development stage in combination with ivacaftor in multiple CF patients; VX-371, an investigational epithelial sodium channel, which is in a Phase II development stage; and VX-152 and VX-440 that are CFTR corrector compounds in Phase I clinical trial. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology.

Leave a Reply

Your email address will not be published. Required fields are marked *